Disclaimer

The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com.
The DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
The DSR® therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe.

HEART FAILURE

Ongoing studies
Published & Presented studies
SAHARA DESERT – ALFAPUMP DSR STUDY IN DECOMPENSATED HEART FAILURE PATIENTS

SAHARA DESERT is a multi-centre, prospective, randomised, open-label study to evaluate the safety and feasibility of alfapump DSR therapy in heart failure patients with persistent congestion and resistance to loop diuretic treatment. Twenty patients will be implanted with the alfapump DSR system. Following alfapump DSR implantation, patients will undergo a diuretic challenge to quantify their response to diuretics, which will be repeated at specific time points throughout the study. At the start of the study treatment period, loop diuretics will be withheld and patients will be randomised 1:1 to DSR therapy with or without SGLT2-inhibitor to evaluate their impact on DSR therapy. Patients will undergo intensive DSR therapy with DSR D10% infusate for two weeks (phase 1) which can be repeated up to two times depending on their euvolemic state, diuretic response and stable DSR dosing at the end of phase 1. Patients who have achieved euvolemia and have adequate diuretic response will enter into the maintenance DSR treatment phase with monthly DSR dosing for 16 weeks (phase 2).

The primary safety and tolerability endpoints include the rate of treatment-, device- or procedure-related serious adverse events through the end of the maintenance phase. Secondary feasibility endpoints include the ability of DSR therapy to restore and maintain euvolemia without the need for additional loop diuretic treatment. Additional exploratory endpoints will evaluate the potential impact of SGLT-2 inhibitors on DSR therapy. The study is being conducted in up to three clinical centres in the Republic of Georgia. For more information about the study, please visit clinicaltrials.gov (NCT04882358).

RED DESERT – ALFAPUMP DSR REPEATED DOSE CLINICAL PROOF OF CONCEPT STUDY

Prospective, single-arm, first-in-human repeated dose study to evaluate the safety and feasibility of alfapump DSR® in diuretic-resistant heart failure patients. Results demonstrated that repeated alfapump DSR therapy could effectively replace patients’ high dose loop diuretics and restore their diuretic response and overall cardio-renal status. These strong results were presented at the Heart Failure 2021 Digital Congress as part of the Late Breaking Science Results and selected for the congress’ Highlights session.

Abstract “First in Human Experience with Alfapump DSR System in Diuretic Resistant Chronic Heart Failure”
Presentation by Dr. Testani at Heart Failure 2021
Webcast by Sequana Medical management on 11 May 2021


DSR® CLINICAL PROOF OF CONCEPT STUDY

First-in-human single dose DSR® proof of concept study to assess safety, tolerability and impact of direct sodium removal therapy in 10 patients receiving peritoneal dialysis (PD). Results selected for late-breaking abstract session at Heart Failure 2019.
Testani et al., Circulation, 2019
Presentation by Dr. Testani at Heart Failure 2019
Webcast by Sequana Medical management and Dr. Testani on 27 May 2019


DSR® PRECLINICAL PROOF OF CONCEPT STUDY

Single dose, single arm preclinical proof of concept study to assess impact of direct sodium removal therapy in 15 healthy pigs and 5 pigs with experimentally induced heart failure via tamponade.

Poster by Testani et al., HFSA, 2018

We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our. Privacy & Cookie Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close